Clinical Analysis of Immune-Related Adverse Events in 78 Patients with Advanced Metastatic Lung Cancer Treated with Immune Checkpoint Inhibitors

• Published in: Journal of clinical pharmacology
• Main Authors: Wang, Yan, Jin, Change, Liu, Shengguo, Li, Chenhui, Qiu, Jinfan, He, Zhengqiang, Wu, Di
• Format: Journal Article
• Language: English
• Published: England 14.12.2023
• Subjects: Immune-related adverse events; immune checkpoint inhibitors; advanced metastatic lung cancer
• ISSN: 1552-4604

To analyze the clinical features and possible risk factors of immune-related adverse events (irAEs) in patients with advanced metastatic lung cancer treated with immune checkpoint inhibitors. The clinical data of 78 patients with advanced metastatic lung cancer who were treated with immune checkpoint inhibitors in the Respiratory Department of Shenzhen People's Hospital from January 2020 to November 2022 were retrospectively analyzed, and the immune-related adverse events and possible risk factors were summarized.Among the 78 patients, 20 patients developed irAEs, including 17 patients with PD-1 inhibitors and 3 patients with PD-L1 inhibitors. Most irAEs for level 1 or 2, characterized by skin toxicity and endocrine toxicity, while most of the cardiotoxicity was grade 3. Median onset time of irAEs was 6.0 weeks (0.9-24.3 weeks). The overall safety of immune checkpoint inhibitors is acceptable. Immune-related adverse events should be diagnosed and treated early. The mortality risk of severe irAEs is high, and clinical attention should be paid to it.The risk of death of severe irAEs is high, and should be paid more attention to clinically. This article is protected by copyright. All rights reserved.